Discover undervalued stocks with Eulerpool.

Subscribe for $2

Clinuvel Pharmaceuticals Stock CUV.AX

Price

11.43
Today +/-
-0.07
Today %
-1.04 %

Clinuvel Pharmaceuticals stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Clinuvel Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Clinuvel Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Clinuvel Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Clinuvel Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Clinuvel Pharmaceuticals Stock Price History

DateClinuvel Pharmaceuticals Price
9/24/202511.43 undefined
9/23/202511.55 undefined
9/22/202511.23 undefined
9/19/202511.84 undefined
9/18/202511.45 undefined
9/17/202511.84 undefined
9/16/202511.21 undefined
9/15/202510.84 undefined
9/12/202510.66 undefined
9/11/202510.67 undefined
9/10/202510.89 undefined
9/9/202510.76 undefined
9/8/202510.89 undefined
9/5/202511.28 undefined
9/4/202510.57 undefined
9/3/202510.40 undefined
9/2/202510.43 undefined
9/1/202510.77 undefined
8/29/202510.64 undefined
8/28/202512.67 undefined
8/27/202513.55 undefined

Clinuvel Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Clinuvel Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Clinuvel Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Clinuvel Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Clinuvel Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Clinuvel Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Clinuvel Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Clinuvel Pharmaceuticals’s growth potential.

Clinuvel Pharmaceuticals Revenue, EBIT and net profit per share

DateClinuvel Pharmaceuticals RevenueClinuvel Pharmaceuticals EBITClinuvel Pharmaceuticals Net Income
2031e177.44 M undefined0 undefined67.52 M undefined
2030e139.59 M undefined72.45 M undefined60.97 M undefined
2029e356.34 M undefined246.41 M undefined184.95 M undefined
2028e139.53 M undefined58.5 M undefined55.06 M undefined
2027e107.9 M undefined49.49 M undefined41.94 M undefined
2026e103.8 M undefined44.44 M undefined38.29 M undefined
202595.02 M undefined45.73 M undefined36.17 M undefined
202495.5 M undefined55.33 M undefined35.64 M undefined
202382.23 M undefined48.01 M undefined30.6 M undefined
202266.17 M undefined35.77 M undefined20.88 M undefined
202148.32 M undefined29.66 M undefined24.73 M undefined
202033.13 M undefined13.96 M undefined15.05 M undefined
201931.61 M undefined17.26 M undefined18.13 M undefined
201825.75 M undefined12.48 M undefined13.22 M undefined
201717.03 M undefined7.06 M undefined7.18 M undefined
20167.03 M undefined-3.34 M undefined-3.12 M undefined
20153.67 M undefined-10.48 M undefined-10.41 M undefined
20142.99 M undefined-5.5 M undefined-5.53 M undefined
20132.9 M undefined-6.88 M undefined-6.8 M undefined
20121.29 M undefined-9.67 M undefined-9.77 M undefined
20112.28 M undefined-11.41 M undefined-11.41 M undefined
20101.85 M undefined-12.36 M undefined-11.52 M undefined
20092.91 M undefined-13.55 M undefined-15.37 M undefined
20084.3 M undefined-14.66 M undefined-14.66 M undefined
20072.55 M undefined-9.06 M undefined-9.18 M undefined
20061.2 M undefined-9.54 M undefined-10.77 M undefined

Clinuvel Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
00000012421212237172531334866829595103107139356139177
-------100.00100.00-50.00-50.00100.00-50.00100.00-50.00133.33142.8647.0624.006.4545.4537.5024.2415.85-8.423.8829.91156.12-60.9627.34
------9,300.004,650.002,325.004,650.009,300.004,650.009,300.004,650.004,650.003,100.001,328.57547.06372.00300.0096.97104.1796.97108.54101.0597.8990.2986.9266.9126.1266.9152.54
00000000000000000000325064899693000000
0-1-3-3-7-11-10-9-14-15-11-11-9-6-5-10-3713181524203035363841551846067
--200.00-133.3357.14-9.09-10.0055.567.14-26.67--18.18-33.33-16.67100.00-70.00-333.3385.7138.46-16.6760.00-16.6750.0016.672.865.567.8934.15234.55-67.3911.67
-------------------0.020.030.030.030.060.070.070.070.080.110.370.120.14
00000000000000000000500010016.670014.2937.5236.36-67.5716.67
7.177.179.039.0911.4413.1416.7724.8230.2430.3130.3230.3630.7635.338.743.3745.2949.6349.5949.650.4651.1351.7851.8251.0350.38000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Clinuvel Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Clinuvel Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (k)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (k)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (k)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025
                                                   
6.576.984.412.615.484.7610.6362.3550.837.752717.513.1712.5714.6310.5713.8423.7536.254.2766.7582.69121.51156.81183.87224.11
0.060.030.030.030.080.140.230.240.620.210.360.971.011.741.591.964.823.245.094.166.6116.0916.222.2126.2427.46
0000040400000000000000000000
000000.030.58000000000.841.081.240.642.141.293.191.839.5210.638.82
0.060.010.040.110.120.272.432.721.72.631.791.461.631.360.830.20.220.240.340.590.510.881.041.071.332.58
6.697.024.482.755.685.2413.9165.3153.1240.5929.1519.9315.8115.6717.0513.5719.9728.4742.2761.1575.16102.85140.58189.62222.06262.97
0.090.120.140.150.120.250.220.330.430.360.320.210.180.150.110.070.160.140.170.712.392.62.72.857.727.13
00000000000000000000000000
0000000000000000000000.280.31.5700
7.356.625.95.174.454.562.932.181.420.660.030.020.010000000000000
000000000000000000185185185185185185185185
0000000000000000000.280.33.812.930.481.061.151.47
7.446.746.045.324.574.813.152.511.851.020.350.230.190.150.110.070.160.140.641.196.3963.675.679.068.78
14.1313.7610.528.0710.2510.0517.0667.8254.9741.6129.520.161615.8217.1613.6420.1428.6142.962.3581.54108.84144.25195.28231.12271.75
                                                   
14.3815.3815.3816.5825.4935.1252.73112.81113.22113.22113.23113.34119.32126.71133.57138.47146.76148.41148.61151.31151.85151.85151.85151.85168.8169.28
00000000000000000000000000
-0.37-1.93-5.07-9.05-16.64-27.67-38.74-47.42-63.09-76.19-86.85-96.94-105.6-112.92-118.26-127.63-129.08-123.15-109.82-94.83-79.88-53.79-28.029.631.1666.1
000000001.680.020.050.01-0.090.050.120.380.110.120.620.70.10.671.733.193.055.43
00000000000000000000000000
14.0113.4510.317.538.857.4513.9965.3951.8137.0526.4316.4113.6313.8415.4311.2217.825.3939.4257.1872.0798.74125.56164.63203.01240.81
0.120.290.160.351.282.492.992.322.974.372.83.442.081.451.111.861.572.292.53.634.774.753.287.657.119.94
000000000000.280.260.490.610.570.720.850.971.073.283.701.451.882.29
0.010.030.050.190.090.090.070.110.180.180.240000000000010.1416.0915.8514.55
00000000000000000000000000
0000000000000000000261.3212.3258.2315.1300.8369.9431.2
0.130.320.210.541.372.583.062.433.154.553.043.722.341.941.722.442.293.153.474.968.268.7113.7325.4925.2127.21
00000000000000000000.171.111.050.940.70.510.1
00000000000000000000003.622.762.233.42
000020202010102040402030103.315.415.317.834.2105.778101.6131.2164213.3
00000.020.020.020.010.010.020.040.040.020.030.0100.020.020.020.211.211.124.663.592.93.73
0.130.320.210.541.392.63.082.443.164.573.083.762.361.971.732.442.33.163.495.179.489.8318.3929.0828.1130.94
14.1413.7710.528.0710.2410.0517.0767.8354.9741.6229.5120.1715.9915.8117.1613.6620.128.5542.962.3581.54108.57143.95193.71231.12271.75
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Clinuvel Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Clinuvel Pharmaceuticals's financial health and stability.

Assets

Clinuvel Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Clinuvel Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Clinuvel Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Clinuvel Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (k)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000000242030
000000000000000000000000
00000000000000000000006-1
00-1000023211120000000002
000000000000000000000468
000000000000000000000000
000000000000001,00000000000-7,000
00-2-3-6-9-11-8-7-10-11-9-10-6-4-4-59111814193936
00000-100000000000000000-1
00000-1-2-26069240000000000-1
000000-1-260692400000000000
000000000000000000000000
000000000000000000000000
710191018610000566080000000
610189176000005660800-1-1-1-1-2
--------1.00----------------
00000000000000000000-1-1-1-1
60-3-5-3-10-814-19-17-15-18-10-9-4-9-218233625347776
-0.38-0.59-2.57-3.12-6.04-10.35-11.76-8.62-7.4-11.02-11.83-9.56-10.02-6.92-4.81-4.54-5.139.8511.6218.213.318.4139.4435.88
000000000000000000000000

Clinuvel Pharmaceuticals stock margins

The Clinuvel Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Clinuvel Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Clinuvel Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Clinuvel Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Clinuvel Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Clinuvel Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Clinuvel Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Clinuvel Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Clinuvel Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Clinuvel Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Clinuvel Pharmaceuticals Margin History

Clinuvel Pharmaceuticals Gross marginClinuvel Pharmaceuticals Profit marginClinuvel Pharmaceuticals EBIT marginClinuvel Pharmaceuticals Profit margin
2031e98.1 %0 %38.05 %
2030e98.1 %51.9 %43.68 %
2029e98.1 %69.15 %51.9 %
2028e98.1 %41.92 %39.46 %
2027e98.1 %45.87 %38.86 %
2026e98.1 %42.81 %36.89 %
202598.1 %48.13 %38.07 %
2024101.16 %57.94 %37.31 %
2023109.35 %58.39 %37.22 %
202297.95 %54.07 %31.55 %
2021103.93 %61.39 %51.18 %
202097.44 %42.14 %45.43 %
201998.1 %54.58 %57.36 %
201898.1 %48.46 %51.36 %
201798.1 %41.48 %42.17 %
201698.1 %-47.54 %-44.41 %
201598.1 %-285.82 %-284.07 %
201498.1 %-183.95 %-184.95 %
201398.1 %-237.24 %-234.48 %
201298.1 %-749.61 %-757.36 %
201198.1 %-500.44 %-500.44 %
201098.1 %-668.11 %-622.7 %
200998.1 %-465.64 %-528.18 %
200898.1 %-340.93 %-340.93 %
200798.1 %-355.29 %-360 %
200698.1 %-795 %-897.5 %

Clinuvel Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Clinuvel Pharmaceuticals earnings per share therefore indicates how much revenue Clinuvel Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Clinuvel Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Clinuvel Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Clinuvel Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Clinuvel Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Clinuvel Pharmaceuticals Revenue, EBIT and net profit per share

DateClinuvel Pharmaceuticals Sales per ShareClinuvel Pharmaceuticals EBIT per shareClinuvel Pharmaceuticals Earnings per Share
2031e3.52 undefined0 undefined1.34 undefined
2030e2.77 undefined0 undefined1.21 undefined
2029e7.07 undefined0 undefined3.67 undefined
2028e2.77 undefined0 undefined1.09 undefined
2027e2.14 undefined0 undefined0.83 undefined
2026e2.06 undefined0 undefined0.76 undefined
20251.89 undefined0.91 undefined0.72 undefined
20241.87 undefined1.08 undefined0.7 undefined
20231.59 undefined0.93 undefined0.59 undefined
20221.28 undefined0.69 undefined0.4 undefined
20210.94 undefined0.58 undefined0.48 undefined
20200.66 undefined0.28 undefined0.3 undefined
20190.64 undefined0.35 undefined0.37 undefined
20180.52 undefined0.25 undefined0.27 undefined
20170.34 undefined0.14 undefined0.14 undefined
20160.16 undefined-0.07 undefined-0.07 undefined
20150.08 undefined-0.24 undefined-0.24 undefined
20140.08 undefined-0.14 undefined-0.14 undefined
20130.08 undefined-0.19 undefined-0.19 undefined
20120.04 undefined-0.31 undefined-0.32 undefined
20110.08 undefined-0.38 undefined-0.38 undefined
20100.06 undefined-0.41 undefined-0.38 undefined
20090.1 undefined-0.45 undefined-0.51 undefined
20080.14 undefined-0.48 undefined-0.48 undefined
20070.1 undefined-0.37 undefined-0.37 undefined
20060.07 undefined-0.57 undefined-0.64 undefined

Clinuvel Pharmaceuticals business model

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company that specializes in researching, developing, and marketing drugs targeting skin pigmentation. The company was founded in 1987 and is headquartered in Melbourne, Australia. It has become a leading expert in the field of light and pigment medicine since its establishment. Clinuvel's business model focuses on utilizing innovative technologies and scientific research to develop new products and therapies that benefit patients worldwide. The company specializes in developing safe and effective drugs based on research in therapeutic areas such as skin pigment disorders and skin cancer prevention. In recent years, the company has expanded its various divisions to meet market demand and extend innovations to other areas of medicine. Clinuvel's main divisions are Pharmaceuticals and Nutraceuticals. Clinuvel's pharmaceutical division specializes in developing new drugs and therapies for modulating skin pigmentation. The company is particularly known for its flagship product, SCENESSE, an implant that allows people with the rare condition erythropoietic protoporphyria (EPP) to live without pain in the sun. SCENESSE has received European and Australian approvals and is prescribed worldwide by a growing network of treatment centers. Clinuvel's nutraceutical division focuses on developing dietary supplements and advising patients who want to improve their skin from within. This includes products like Cuvita, a dietary supplement containing antioxidants and other nutrients that can contribute to the health of hair, skin, and nails. Clinuvel has expanded its business models to meet the needs of patients in different regions of the world. For example, the company has developed a comprehensive integration strategy in Europe to promote research, development, and marketing of innovative products and therapies. Overall, Clinuvel Pharmaceuticals is a company that focuses on developing innovative drugs and therapies in the field of light and pigment medicine. It is known for its advanced research, successful development of SCENESSE, and commitment to patients worldwide. It will be interesting to see how the divisions develop in the future, but innovative drugs and therapies are definitely an important part of Clinuvel's future. Clinuvel Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Clinuvel Pharmaceuticals SWOT Analysis

Strengths

Clinuvel Pharmaceuticals Ltd possesses several strengths that contribute to its competitive advantage:

Clinuvel offers a unique and innovative product portfolio, focused on pharmaceuticals to address severe skin disorders.

The company has a robust R&D division, enabling it to continuously develop and improve new treatments, establishing a strong pipeline of products.

Clinuvel has built a solid reputation in the pharmaceutical industry and has gained market recognition for its products.

The company has established distribution channels across multiple regions, allowing it to reach a global customer base effectively.

Weaknesses

Clinuvel Pharmaceuticals Ltd should address the following weaknesses to enhance its competitive position:

Clinuvel's product portfolio is currently focused on a narrow niche market, which can increase vulnerability to changes in market demand and competition.

The pharmaceutical industry is subject to strict regulatory requirements, and Clinuvel needs to remain compliant with these regulations, which may pose challenges and increase costs.

Clinuvel relies heavily on its primary drug SCENESSE®, which may expose the company to risks associated with any setbacks or market challenges faced by this specific product.

Opportunities

Clinuvel Pharmaceuticals Ltd can capitalize on the following opportunities to drive growth:

Clinuvel can explore untapped geographical markets to expand its customer base and increase revenue streams.

Strategic collaborations and partnerships with other pharmaceutical companies or research organizations can facilitate access to new technologies, resources, or expertise.

Clinuvel can invest in the development and acquisition of new products or therapies to diversify its product portfolio and reduce dependency on a single drug.

Threats

Clinuvel Pharmaceuticals Ltd faces the following threats that could impact its business:

The pharmaceutical industry is highly competitive, with numerous players offering treatments for similar indications, which can impact Clinuvel's market share and profitability.

Clinuvel operates in an environment where protecting intellectual property rights is crucial. The risk of infringement and patent expiration of its products can lead to increased competition and revenue losses.

Regulatory requirements and policies can change, impacting the launch and market availability of Clinuvel's products. Compliance with evolving regulations demands resources and may cause delays.

Economic downturns or fluctuations can affect consumer spending on healthcare and pharmaceutical products, potentially reducing demand for Clinuvel's offerings.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Clinuvel Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Clinuvel Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Clinuvel Pharmaceuticals shares outstanding

The number of shares was Clinuvel Pharmaceuticals in 2024 — This indicates how many shares 51.027 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Clinuvel Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Clinuvel Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Clinuvel Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Clinuvel Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Clinuvel Pharmaceuticals stock splits

In Clinuvel Pharmaceuticals's history, there have been no stock splits.

Clinuvel Pharmaceuticals dividend history and estimates

In 2024, Clinuvel Pharmaceuticals paid a dividend amounting to 0.07 undefined. Dividend means that Clinuvel Pharmaceuticals distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Clinuvel Pharmaceuticals provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Clinuvel Pharmaceuticals’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Clinuvel Pharmaceuticals's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Clinuvel Pharmaceuticals Dividend History

DateClinuvel Pharmaceuticals Dividend
2031e0.14 undefined
2030e0.12 undefined
2029e0.37 undefined
2028e0.11 undefined
2027e0.08 undefined
20260.07 undefined
20250.07 undefined
20240.07 undefined
20230.06 undefined
20220.03 undefined
20210.03 undefined
20200.03 undefined
20190.02 undefined

Clinuvel Pharmaceuticals dividend payout ratio

In 2024, Clinuvel Pharmaceuticals had a payout ratio of 9.53%. The payout ratio indicates the percentage of the company's profits that Clinuvel Pharmaceuticals distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Clinuvel Pharmaceuticals represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Clinuvel Pharmaceuticals could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Clinuvel Pharmaceuticals's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Clinuvel Pharmaceuticals Payout Ratio History

DateClinuvel Pharmaceuticals Payout ratio
2031e10.23 %
2030e10.21 %
2029e10.13 %
2028e10.35 %
2027e10.14 %
2026e9.92 %
202510.98 %
20249.53 %
20239.24 %
202214.17 %
20215.17 %
20208.38 %
20196.84 %
20187.5 %
20179.24 %
20169.24 %
20159.24 %
20149.24 %
20139.24 %
20129.24 %
20119.24 %
20109.24 %
20099.24 %
20089.24 %
20079.24 %
20069.24 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Clinuvel Pharmaceuticals.

Clinuvel Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20250.47 0.44  (-6.33 %)2025 Q4
12/31/20240.2 0.28  (39.65 %)2025 Q2
6/30/20240.42 0.49  (15.25 %)2024 Q4
12/31/20230.26 0.21  (-18.96 %)2024 Q2
6/30/20230.34 0.37  (9.63 %)2023 Q4
12/31/20220.25 0.22  (-12 %)2023 Q2
6/30/20220.29 0.29  (-0.99 %)2022 Q4
12/31/20210.24 0.11  (-52.58 %)2022 Q2
6/30/20210.23 0.36  (57.06 %)2021 Q4
12/31/20200.22 0.13  (-42.06 %)2021 Q2
1

Eulerpool ESG Scorecard© for the Clinuvel Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

2

👫 Social

61

🏛️ Governance

39

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees64
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Clinuvel Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
6.79883 % Wolgen (Philippe Jacques)3,425,22206/30/2024
5.14261 % Ender 1, L.L.C.2,590,82408/15/2024
2.48553 % The Vanguard Group, Inc.1,252,19907/31/2025
1.37945 % Vanguard Investments Australia Ltd.694,959-916/30/2025
1.19383 % Emilino Group Pty. Ltd.601,447-2,0008/15/2024
0.97269 % Norges Bank Investment Management (NBIM)490,03552,31912/31/2024
0.92913 % Dimensional Fund Advisors, L.P.468,09107/31/2025
0.78845 % Macquarie Investment Management Global Ltd.397,2164,29512/31/2024
0.72031 % Keamy (Darren M)362,890184,3026/30/2024
0.68832 % Badcock (Mark Edwin)346,772-93,3138/15/2024
1
2
3
4
5
...
8

Clinuvel Pharmaceuticals Executives and Management Board

Dr. Philippe Wolgen

Clinuvel Pharmaceuticals Chief Executive Officer, Managing Director, Executive Director (since 2005)
Compensation 3.74 M

Dr. Dennis Wright

Clinuvel Pharmaceuticals Chief Scientific Officer (since 2020)
Compensation 782,613

Prof. Jeffrey Rosenfeld

Clinuvel Pharmaceuticals Non-Executive Chairman of the Board
Compensation 91,667

Mrs. Brenda Shanahan

Clinuvel Pharmaceuticals Non-Executive Independent Director
Compensation 85,001

Mrs. Susan Smith

Clinuvel Pharmaceuticals Non-Executive Independent Director
Compensation 80,000
1
2
3
4

Clinuvel Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
HSBC Holdings Stock
HSBC Holdings
SupplierCustomer0,660,710,45-0,68-0,74-0,06
BNP Paribas A Stock
BNP Paribas A
SupplierCustomer0,55-0,370,770,590,210,45
JPMorgan Chase Stock
JPMorgan Chase
SupplierCustomer0,450,780,890,920,800,61
1

Most common questions regarding Clinuvel Pharmaceuticals

What values and corporate philosophy does Clinuvel Pharmaceuticals represent?

Clinuvel Pharmaceuticals Ltd represents values and a corporate philosophy focused on delivering innovative, science-driven therapeutic solutions. The company is committed to advancing knowledge and improving the lives of patients suffering from severe skin disorders. Clinuvel's passion for the scientific community and dedication to patient well-being is evident in their development of SCENESSE®, a groundbreaking drug for the treatment of rare genetic skin diseases. With a strong emphasis on research, development, and collaboration, Clinuvel Pharmaceuticals Ltd strives to provide innovative and effective treatments, revolutionizing the way severe skin disorders are managed.

In which countries and regions is Clinuvel Pharmaceuticals primarily present?

Clinuvel Pharmaceuticals Ltd is primarily present in Australia, Europe, the United States, and other select regions globally. As a leading pharmaceutical company, Clinuvel focuses on developing and commercializing innovative therapies to treat various severe skin disorders. With a strong presence in these key markets, Clinuvel Pharmaceuticals Ltd strives to provide patients with effective and safe treatments to improve their quality of life.

What significant milestones has the company Clinuvel Pharmaceuticals achieved?

Clinuvel Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully obtained marketing approvals in the European Union for its product SCENESSE®, a first-line treatment for erythropoietic protoporphyria (EPP). This approval marked a major milestone for the company as it became the first-ever approved therapy for EPP patients. Additionally, Clinuvel Pharmaceuticals Ltd expanded its commercialization efforts by gaining market access in Switzerland, Australia, and the United States. Furthermore, the company demonstrated robust clinical trial data highlighting the safety and efficacy of SCENESSE®. Clinuvel's achievements in securing approvals, expanding market access and delivering substantial clinical evidence demonstrate its dedication towards improving the lives of patients with rare genetic disorders like EPP.

What is the history and background of the company Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals Ltd is an Australian biopharmaceutical company specializing in the development and commercialization of therapies for genetic diseases. Founded in 1987, Clinuvel has dedicated years to research and development, focusing on photoprotection and pigmentation disorders. The company gained recognition for its flagship product, SCENESSE®, a treatment for the rare genetic disorder erythropoietic protoporphyria (EPP). Clinuvel Pharmaceuticals continues to explore potential applications of its innovative technology in various medical fields, aiming to improve the lives of patients worldwide. With a strong commitment to scientific excellence and continuous advancement, Clinuvel Pharmaceuticals Ltd remains a key player in the field of biopharmaceuticals.

Who are the main competitors of Clinuvel Pharmaceuticals in the market?

The main competitors of Clinuvel Pharmaceuticals Ltd in the market are other pharmaceutical companies that specialize in developing and commercializing pharmaceutical products.

In which industries is Clinuvel Pharmaceuticals primarily active?

Clinuvel Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

What is the business model of Clinuvel Pharmaceuticals?

The business model of Clinuvel Pharmaceuticals Ltd is focused on developing and commercializing pharmaceutical products for the treatment of severe genetic and skin disorders. The company specializes in innovative solutions for patients suffering from rare and ultra-rare diseases. With a strong emphasis on research and development, Clinuvel aims to improve the quality of life for individuals affected by these conditions. By leveraging its expertise in photoprotection and photorepair, Clinuvel seeks to address unmet medical needs, providing effective treatments that can significantly impact patients' lives. Clinuvel Pharmaceuticals Ltd is dedicated to advancing healthcare solutions and making a positive difference in the lives of those it serves.

What is the P/E ratio of Clinuvel Pharmaceuticals 2025?

The Clinuvel Pharmaceuticals P/E ratio is 15.92.

What is the P/S ratio of Clinuvel Pharmaceuticals 2025?

The Clinuvel Pharmaceuticals P/S ratio is 6.06.

What is the Quality Investing of Clinuvel Pharmaceuticals?

The Quality Investing for Clinuvel Pharmaceuticals is 7/10.

What is the revenue of Clinuvel Pharmaceuticals 2025?

The Clinuvel Pharmaceuticals revenue is 95.02 M AUD.

How high is the profit of Clinuvel Pharmaceuticals 2025?

The Clinuvel Pharmaceuticals profit is 36.17 M AUD.

What is the business model of Clinuvel Pharmaceuticals

The Australian company Clinuvel Pharmaceuticals Ltd is a biotech company specializing in developing innovative therapeutics for various skin diseases. The company focuses on researching and developing products for the treatment of rare diseases and difficult-to-treat skin conditions. Clinuvel operates three main business lines: Pharma, Cosmeceutical, and Heritage. The Pharma division of Clinuvel is the flagship of the company and includes a wide range of medical products for the treatment of various skin diseases. Clinuvel has developed an innovative drug called SCENESSE, which is approved for the treatment of patients with Erythropoietic Protoporphyria (EPP). EPP is a rare genetic disorder that causes patients to have an extremely painful sensitivity to visible light. The Cosmeceutical division of Clinuvel focuses on the development of cosmetic products that combat skin aging and keep the skin healthy and youthful. The products are typically enriched with powerful antioxidants and moisturizing agents to protect the skin and reduce the appearance of aging signs. The Heritage division of Clinuvel specializes in developing products for maintaining cultural identity and heritage preservation. These products relate to the traditions and customs of specific cultures and communities, thereby supporting the preservation of these important cultural features. Clinuvel's business model is based on a strong research and development strategy to create innovative products that provide clinical benefits and improve patients' lives. The company also has a strong focus on compliance regulations and the safety of its products. To achieve its goals, Clinuvel has established a global presence and works closely with leading experts in the pharmaceutical and biotechnology industry. The company also has strategic partnerships with non-profit organizations and other companies to expand its range of products and services. Clinuvel's goal is to provide groundbreaking solutions for the treatment of skin diseases while improving the quality of life for patients. The company aims to expand its global presence by remaining innovative and actively seeking new partnerships.

What is the Clinuvel Pharmaceuticals dividend?

Clinuvel Pharmaceuticals pays a dividend of 0.06 AUD distributed over 1 payouts per year.

How often does Clinuvel Pharmaceuticals pay dividends?

Clinuvel Pharmaceuticals pays out a dividend 1 times a year.

What is the Clinuvel Pharmaceuticals ISIN?

The ISIN of Clinuvel Pharmaceuticals is AU000000CUV3.

What is the Clinuvel Pharmaceuticals WKN?

The WKN of Clinuvel Pharmaceuticals is A0JEGY.

What is the Clinuvel Pharmaceuticals ticker?

The ticker of Clinuvel Pharmaceuticals is CUV.AX.

How much dividend does Clinuvel Pharmaceuticals pay?

Over the past 12 months, Clinuvel Pharmaceuticals paid a dividend of 0.07 AUD . This corresponds to a dividend yield of about 0.62 %. For the coming 12 months, Clinuvel Pharmaceuticals is expected to pay a dividend of 0.08 AUD.

What is the dividend yield of Clinuvel Pharmaceuticals?

The current dividend yield of Clinuvel Pharmaceuticals is 0.62 %.

When does Clinuvel Pharmaceuticals pay dividends?

Clinuvel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of October, October, October, October.

How secure is the dividend of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals paid dividends every year for the past 13 years.

What is the dividend of Clinuvel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.08 AUD are expected. This corresponds to a dividend yield of 0.72 %.

In which sector is Clinuvel Pharmaceuticals located?

Clinuvel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clinuvel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clinuvel Pharmaceuticals from 9/19/2025 amounting to 0.071 AUD, you needed to have the stock in your portfolio before the ex-date on 9/4/2025.

When did Clinuvel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/19/2025.

What was the dividend of Clinuvel Pharmaceuticals in the year 2024?

In the year 2024, Clinuvel Pharmaceuticals distributed 0.071 AUD as dividends.

In which currency does Clinuvel Pharmaceuticals pay out the dividend?

The dividends of Clinuvel Pharmaceuticals are distributed in AUD.

All fundamentals about Clinuvel Pharmaceuticals

Our stock analysis for Clinuvel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clinuvel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.